View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika Budapest Szentkirályi u. 46. 1083
Restricted access

A cardiovascularis halálozás világszerte növekszik. A halálos kimenetelnek egyik legfontosabb kóroki tényezője a diabetes mellitus. E megbetegedés kezelésére alkalmazható gyógyszerek közé tartoznak az inzulin kiválasztását fokozó szerek (insulinsecretagog készítmények), az inzulin hatását növelő (inzulinszenzitizálók) és glükózfelszívódást gátló készítmények. Mindezek alkalmazhatók monoterápiában és különféle kombinációban is. A gyakorlatban nagyon hasznosnak tűnik a roziglitazon és a glimepirid kombinációja. Mivel alkotóik különböző támadáspontokon fejtik ki hatásukat, jól kiegészítik egymást. A glimepirid a béta-sejtek inzulinszekrécióját fokozza, csökkenti a vércukorszintet, a roziglitazon pedig az így megtermelt inzulin iránti érzékenységet fokozza a célszervekben. A két szer additív módon jelentősen javítja a vércukorszintet. A glimepirid és roziglitazon kombinációját a betegek általában jól tolerálják, és a fix kombináció javítja a terápiás adherenciát is.

  • Fehér J., Lengyel G.: Táplálkozás és a szív- és érrendszeri betegségek miatti halálozás. Orv. Hetil., 2006, 147 , 1491–1496.

    Lengyel G. , 'Táplálkozás és a szív- és érrendszeri betegségek miatti halálozás ' (2006 ) 147 Orv. Hetil. : 1491 -1496.

    • Search Google Scholar
  • Derosa, G., Cicero, A. F. G., D’Angelo, A. és mtsai: Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens. Res., 2005, 28 , 917–924.

    D’Angelo A. , 'Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride ' (2005 ) 28 Hypertens. Res. : 917 -924.

    • Search Google Scholar
  • Fukuen, S., Iwaki, M., Yasui, A. és mtsai: Sulfonylurea agents exhibit peroxisome proliferator-activated receptor agonistic activity. J. Biol. Chem., 2005, 280 , 23653–23659.

    Yasui A. , 'Sulfonylurea agents exhibit peroxisome proliferator-activated receptor agonistic activity ' (2005 ) 280 J. Biol. Chem. : 23653 -23659.

    • Search Google Scholar
  • Pfützner, A., Wilhelm, B., Forst, T.: Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination. Vasc. Health Risk Manag., 2007, 3 , 211–220.

    Forst T. , 'Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination ' (2007 ) 3 Vasc. Health Risk Manag. : 211 -220.

    • Search Google Scholar
  • Sheehan, M. T.: Current Therapeutic Options in Type 2 Diabetes Mellitus: A Practical Approach. Clinical Medicine & Research, 2003, 1 , 189–200.

    Sheehan M. T. , 'Current Therapeutic Options in Type 2 Diabetes Mellitus: A Practical Approach ' (2003 ) 1 Clinical Medicine & Research : 189 -200.

    • Search Google Scholar
  • Zimmerman, B. R.: Sulfonylureas. Endocrinol Metab. Clin. North Am., 1997, 26 , 511–522.

    Zimmerman B. R. , 'Sulfonylureas ' (1997 ) 26 Endocrinol Metab. Clin. North Am. : 511 -522.

  • Fukuen, S., Iwaki, M., Yasui, A. és mtsai: Sulfonylurea Agents Exhibit Peroxisome Proliferator-activated Receptor γ Agonistic Activity. J. Biol. Chem., 2005, 280 , 23653–23659.

    Yasui A. , 'Sulfonylurea Agents Exhibit Peroxisome Proliferator-activated Receptor γ Agonistic Activity ' (2005 ) 280 J. Biol. Chem. : 23653 -23659.

    • Search Google Scholar
  • Damsbo, P., Clauson, P., Marbury, T. C. és mtsa: A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care, 1999, 22 , 789–794.

    Marbury T. C. , 'A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients ' (1999 ) 22 Diabetes Care : 789 -794.

    • Search Google Scholar
  • DeFronzo, R. A., Goodman, A. M.: The Multicenter Metformin Study Group. Efficacy of metformin in patients with noninsulin-dependent diabetes mellitus. N. Engl. J. Med., 1995, 333 , 541–549.

    Goodman A. M. , 'The Multicenter Metformin Study Group. Efficacy of metformin in patients with noninsulin-dependent diabetes mellitus ' (1995 ) 333 N. Engl. J. Med. : 541 -549.

    • Search Google Scholar
  • Hundal, R. S, Krssak, M., Dufour, S. és mtsai: Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes, 2000, 49 , 2063–2069.

    Dufour S. , 'Mechanism by which metformin reduces glucose production in type 2 diabetes ' (2000 ) 49 Diabetes : 2063 -2069.

    • Search Google Scholar
  • Abbasi, F., Carantoni, M., Chen, Y. D. és mtsai: Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin. Diabetes Care, 1998, 21 , 1301–1305.

    Chen Y. D. , 'Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin ' (1998 ) 21 Diabetes Care : 1301 -1305.

    • Search Google Scholar
  • Palumbo, P. J.: Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J. Diabetes Complications, 1998, 12 , 110–119.

    Palumbo P. J. , 'Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus ' (1998 ) 12 J. Diabetes Complications : 110 -119.

    • Search Google Scholar
  • UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998, 352 , 854–865.

    'Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) ' (1998 ) 352 Lancet : 854 -865.

    • Search Google Scholar
  • Garber, A. J., Duncan, T. G., Goodman, A. M. és mtsai: Efficacy of metformin in type II diabetes: results of a doubleblind, placebo-controlled, dose-response trial. Am. J. Med., 1997, 103 , 491–497.

    Goodman A. M. , 'Efficacy of metformin in type II diabetes: results of a doubleblind, placebo-controlled, dose-response trial ' (1997 ) 103 Am. J. Med. : 491 -497.

    • Search Google Scholar
  • Lebovitz, H. E., Kreider, M., Freed, M. I.: Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care, 2002, 25 , 815–821.

    Freed M. I. , 'Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction ' (2002 ) 25 Diabetes Care : 815 -821.

    • Search Google Scholar
  • Ovalle, F., Bell, D. S. H.: Effect of Rosiglitazone Versus Insulin on the Pancreatic Cell Function of Subjects With Type 2 Diabetes. Diabetes Care, 2004, 27 , 2585–2589.

    Bell D. S. H. , 'Effect of Rosiglitazone Versus Insulin on the Pancreatic Cell Function of Subjects With Type 2 Diabetes ' (2004 ) 27 Diabetes Care : 2585 -2589.

    • Search Google Scholar
  • Viberti, G., Kahn, S. E., Greene, D. A. és mtsai: A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care, 2002, 25 , 1737–1743.

    Greene D. A. , 'A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes ' (2002 ) 25 Diabetes Care : 1737 -1743.

    • Search Google Scholar
  • Freed, M. I., Ratner, R., Marcovina, S. M. és mtsai: Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am. J. Cardiol., 2002, 90 , 947–952.

    Marcovina S. M. , 'Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus ' (2002 ) 90 Am. J. Cardiol. : 947 -952.

    • Search Google Scholar
  • Parulkar, A. A., Pendergrass, M. L., Granda-Ayala, R. és mtsai: Nonhypoglycemic effects of thiazolidinediones. Ann. Intern. Med., 2001, 134 , 61–71.

    Granda-Ayala R. , 'Nonhypoglycemic effects of thiazolidinediones ' (2001 ) 134 Ann. Intern. Med. : 61 -71.

    • Search Google Scholar
  • Raji, A., Plutzky, J.: Insulin resistance, diabetes and atherosclerosis: thiazolidinediones as therapeutic interventions. Curr. Cardiol. Rep., 2002, 4 , 514–521.

    Plutzky J. , 'Insulin resistance, diabetes and atherosclerosis: thiazolidinediones as therapeutic interventions ' (2002 ) 4 Curr. Cardiol. Rep. : 514 -521.

    • Search Google Scholar
  • Mittermayer, F., Schaller, G., Pleiner, J. és mtsai: Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction. M. J. Clin. Endocrinol. Metab., 2007. May 1.; [Epub ahead of print.

  • Kerenyi, Zs., Samer, H., James, R. és mtsai: Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2004, 63 , 213–223.

    James R. , 'Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus ' (2004 ) 63 Diabetes Research and Clinical Practice : 213 -223.

    • Search Google Scholar
  • Home, P. D., Pocock, S. J., Beck-Nielsen, H. és mtsai: Rosiglitazone Evaluated for Cardiovascular Outcomes – An Interim Analysis. NEJM, 2007, 357 , 28–38.

    Beck-Nielsen H. , 'Rosiglitazone Evaluated for Cardiovascular Outcomes – An Interim Analysis ' (2007 ) 357 NEJM : 28 -38.

    • Search Google Scholar
  • Kim, H. J, Kang, E. S., Kim, D. J. és mtsai: Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clinical Endocrinology, 2007, 66 , 282–289.

    Kim D. J. , 'Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus ' (2007 ) 66 Clinical Endocrinology : 282 -289.

    • Search Google Scholar
  • Psaty, B. M., Furberg, C. D.: The record on rosiglitazone and the risk of myocardial infarction. N. Engl. J. Med., 2007, 357 , 67–69.; Epub. 2007. Jun. 5.

    Furberg C. D. , 'The record on rosiglitazone and the risk of myocardial infarction ' (2007 ) 357 N. Engl. J. Med. : 67 -69.

    • Search Google Scholar
  • de Dios, S. T., Frontanilla, K. V., Nigro, J. és mtsai: Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents. J. Diabetes Complicat., 2007, 21 , 108–117.

    Nigro J. , 'Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents ' (2007 ) 21 J. Diabetes Complicat. : 108 -117.

    • Search Google Scholar
  • de Dios, S. T., Bruemmer, D., Dilley, R. J. és mtsai: Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery and saphenous vein smooth muscle cell proliferation. Circulation, 2003, 107 , 2548–2550.

    Dilley R. J. , 'Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery and saphenous vein smooth muscle cell proliferation ' (2003 ) 107 Circulation : 2548 -2550.

    • Search Google Scholar
  • Haberbosch, W.: Einfluss der Thiazolidindione auf die diabetestypische Dyslipidämie: Wirken alle gleichermaßen gefäßprotektiv? Herz, 2007, 32 , 51–57.

    Haberbosch W. , 'Einfluss der Thiazolidindione auf die diabetestypische Dyslipidämie: Wirken alle gleichermaßen gefäßprotektiv? ' (2007 ) 32 Herz : 51 -57.

    • Search Google Scholar
  • Jermendy Gy.: Új fix kombináció a 2-es típusú diabetesz kezelésében.; Medical Tribune, 2007, 18.

  • Pfützner, A., Schöndorf, T., Seidel, D. és mtsai: Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Metabol. Clin. Exp., 2006, 55 , 20–25.

    Seidel D. , 'Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride ' (2006 ) 55 Metabol. Clin. Exp. : 20 -25.

    • Search Google Scholar
All Time Past Year Past 30 Days
Abstract Views 63 63 6
Full Text Views 17 2 0
PDF Downloads 5 0 0